Literature DB >> 22766578

Intraindividual differences between two simultaneous glucose measurement systems in type 2 diabetic patients.

Lars Stechemesser1, Agnes Hammerschmied, Brigitta Gappmayer, Mynda Schreuer, Raimund Weitgasser.   

Abstract

AIMS: Continuous glucose measurement systems are an established tool to support diabetes therapy. Because of different technical solutions one can propose different potential limitations in daily practice. So we tried to identify the accuracy of two different devices head to head in daily routine to point out individual characteristics.
METHODS: We included 24 patients with type 2 diabetes mellitus to wear the GlucoDay and the MiniMed continuous glucose measurement system at the same time for 48 h. We examined the mean differences in simultaneous glucose measurements, the confidence intervals were calculated by standard methods based on the t-distribution.
RESULTS: Comparison of glucose levels of both continuous glucose measurement systems showed that there was a tendency for higher glucose levels measured by the GlucoDay device. These differences were dependent on the time of the day. The absolute difference between two consecutive glucose measurements was higher for the GlucoDay system what means a somehow higher fluctuation of the GlucoDay measurements.
CONCLUSIONS: The differences in intraindividual comparison of the GlucoDay and the MiniMed continuous glucose measurement systems in type 2 diabetic patients may be taken into account when using different systems for detection of nocturnal hypoglycemia and the observation of trends used for therapeutic decisions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766578     DOI: 10.1007/s00508-012-0201-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  23 in total

1.  Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study.

Authors:  B W Bode; T M Gross; K R Thornton; J J Mastrototaro
Journal:  Diabetes Res Clin Pract       Date:  1999-12       Impact factor: 5.602

2.  Tests of glycemia in diabetes.

Authors:  David E Goldstein; Randie R Little; Rodney A Lorenz; John I Malone; David M Nathan; Charles M Peterson
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

Review 3.  Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review.

Authors:  Laura M C Welschen; Evelien Bloemendal; Giel Nijpels; Jacqueline M Dekker; Robert J Heine; Wim A B Stalman; Lex M Bouter
Journal:  Diabetes Care       Date:  2005-06       Impact factor: 19.112

4.  Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring.

Authors:  Dorothee Deiss; Jan Bolinder; Jean-Pierre Riveline; Tadej Battelino; Emanuele Bosi; Nadia Tubiana-Rufi; David Kerr; Moshe Phillip
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

5.  Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial.

Authors:  Robert Tanenberg; Bruce Bode; Wendy Lane; Claresa Levetan; Jorge Mestman; Anne Peters Harmel; Janet Tobian; Todd Gross; John Mastrototaro
Journal:  Mayo Clin Proc       Date:  2004-12       Impact factor: 7.616

6.  Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis.

Authors:  Alberto Maran; Cristina Crepaldi; Antonio Tiengo; Giorgio Grassi; Emanuela Vitali; Gianfranco Pagano; Sergio Bistoni; Giuseppe Calabrese; Fausto Santeusanio; Frida Leonetti; Maria Ribaudo; Umberto Di Mario; Giovanni Annuzzi; Salvatore Genovese; Gabriele Riccardi; Marcello Previti; Domenico Cucinotta; Francesco Giorgino; Aurelia Bellomo; Riccardo Giorgino; Alessandro Poscia; Maurizio Varalli
Journal:  Diabetes Care       Date:  2002-02       Impact factor: 19.112

7.  Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.

Authors:  A Avignon; A Radauceanu; L Monnier
Journal:  Diabetes Care       Date:  1997-12       Impact factor: 19.112

8.  Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs.

Authors:  Bruno Guerci; Michèle Floriot; Philip Böhme; Danielle Durain; Muriel Benichou; Stéphanie Jellimann; Pierre Drouin
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

9.  Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Authors:  William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing
Journal:  N Engl J Med       Date:  2008-09-08       Impact factor: 91.245

10.  Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial.

Authors: 
Journal:  Diabetes Care       Date:  2009-10-16       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.